CHAPLE Syndrome — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2022 To 2032
Abnormal activation of the complement system due to biallelic loss-of-function mutations in CD55 leads to CHAPLE syndrome, characterized by hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy. The main symptoms of CHAPLE disease include hypoproteinemia, malabsorption syndrome, complement overactivation, bowel inflammation, and increased susceptibility to visceral thrombosis. The disease typically presents in early childhood with gastrointestinal symptoms, such as diarrhea, vomiting, and GI discomfort, as well as facial and extremity edema due to hypoalbuminemia and failure to thrive. Hypoalbuminemia is the most common finding in CHAPLE disease and can be severe, with serum values below 1 g/dl possible. However, the long-term prognosis is unpredictable, as abrupt relapses can occur even after prolonged periods of remission.
Thelansis’s “CHAPLE Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2021 To 2032” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential CHAPLE Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of CHAPLE Syndrome across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
CHAPLE Syndrome Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
